Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Federal Trade Commission
Boehringer Ingelheim
Daiichi Sankyo

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019600

« Back to Dashboard

NDA 019600 describes OXSORALEN-ULTRA, which is a drug marketed by Dow Pharm and is included in one NDA. It is available from two suppliers. Additional details are available on the OXSORALEN-ULTRA profile page.

The generic ingredient in OXSORALEN-ULTRA is methoxsalen. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.

Summary for 019600

Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 019600

Mechanism of ActionPhotoabsorption
Physiological EffectPhotosensitizing Activity

Medical Subject Heading (MeSH) Categories for 019600

Suppliers and Packaging for NDA: 019600

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXSORALEN-ULTRA methoxsalen CAPSULE;ORAL 019600 NDA Valeant Pharmaceuticals North America LLC 0187-0650 0187-0650-42 50 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0187-0650-42)
OXSORALEN-ULTRA methoxsalen CAPSULE;ORAL 019600 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-065 68682-065-10 50 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (68682-065-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Oct 30, 1986TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 019600

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dow PharmOXSORALEN-ULTRAmethoxsalenCAPSULE;ORAL019600-001Oct 30, 1986► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: